Pharmaceutical Industry Information Portal


All posts by tag


Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment

Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) has authorized the emergency use of PAXLOVID™ (nirmatrelvir tablets and ritonavir tablets)...

FDA Authorizes Additional COVID-19 Vaccine Dose for Certain Immunocompromised Individuals

The FDA evaluated information on the use of a third dose of the Pfizer-BioNTech or Moderna Vaccines and determined that the administration of third vaccine doses may increase protection in this population.

Comirnaty and Spikevax: possible link to very rare cases of myocarditis and pericarditis

At this point in time, no causal relationship with myocarditis or pericarditis could be established with two other COVID-19 vaccines authorised in the EEA, COVID-19 Vaccine Janssen and Vaxzevria.

Pfizer halts distribution of anti-smoking drug after finding carcinogen

Pfizer Inc said on Thursday it is pausing distribution of its anti-smoking treatment, Chantix, after finding elevated levels of cancer-causing agents called nitrosamines in...

FDA Approves Pfizer’s Pneumococcal 20-valent Conjugate Vaccine For Adults

The U.S. Food and Drug Administration has approved Pfizer Inc.'s (PFE) PREVNAR 20 or Pneumococcal 20-valent Conjugate Vaccine for the prevention of invasive disease and pneumonia caused by the 20 Streptococcus pneumoniae or pneumococcus serotypes in the vaccine in adults ages 18 years and older.

Expert Articles